| Description | AV-101 (4-Cl-KYN) , a prodrug antagonist at the glycine site of the NMDA receptor, has antidepressant activity and reduces levodopa-induced dyskinesia in MPTP monkeys. |
| Synonyms | L-4-Cl-KYN, L-4-chlorokynurenine, 4-Cl-KYN, 4ClKYN, 4-Chlorokynurenine, (S)-4-Chlorokynurenine |
| molecular weight | 242.66 |
| Molecular formula | C10H11ClN2O3 |
| CAS | 153152-32-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Yaksh TL, et al. Characterization of the Effects of L-4-Chlorokynurenine on Nociception in Rodents. J Pain. 2017 Oct;18(10):1184-1196. 2. Tan L, Yu JT, Tan L. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations. J Neurol Sci. 2012 Dec 15;323(1-2):1-8. doi: 10.1016/j.jns.2012.08.005. Epub 2012 Aug 29. Review. PubMed PMID: 22939820. 3. Linderholm KR, Andersson A, Olsson S, Olsson E, Snodgrass R, Engberg G, Erhardt S. Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: a pharmacological analysis. Neuropharmacology. 2007 Dec;53(8):918-24. Epub 2007 Sep 20. PubMed PMID: 17959203. 4. Wu HQ, Rassoulpour A, Goodman JH, Scharfman HE, Bertram EH, Schwarcz R. Kynurenate and 7-chlorokynurenate formation in chronically epileptic rats. Epilepsia. 2005 Jul;46(7):1010-6. PubMed PMID: 16026552. |